1.
Siegel R,
Desantis C,
Jemal A.
Colorectal cancer statistics,
2014.
CA: a cancer journal for clinicians.
2014;64(2):104-17.
Epub 2014/03/19.
2.
Benson AB,
3rd.
Epidemiology,
disease progression,
and economic burden of colorectal cancer.
J Manag Care Pharm.
2007;13(6 Suppl C):S5-18.
Epub 2007/10/13.
3.
Clancy C,
Burke JP,
Barry M,
Kalady MF,
Calvin Coffey J.
A Meta-Analysis to Determine the Effect of Primary Tumor Resection for Stage IV Colorectal Cancer with Unresectable Metastases on Patient Survival.
Annals of surgical oncology.
2014;21(12):3900-8.
Epub 2014/05/23.
4.
Ayez N,
Lalmahomed ZS,
Eggermont AM,
Ijzermans JN,
de Jonge J,
van Montfort K,
et al.
Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy.
Annals of surgical oncology.
2012;19(5):1618-27.
Epub 2011/10/19.
5.
Clavien PA,
Barkun J,
de Oliveira ML,
Vauthey JN,
Dindo D,
Schulick RD,
et al.
The Clavien-Dindo classification of surgical complications: five-year experience.
Annals of surgery.
2009;250(2):187-96.
Epub 2009/07/30.
6.
Ruers TJ,
Joosten JJ,
Wiering B,
Langenhoff BS,
Dekker HM,
Wobbes T,
et al. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study.
Annals of surgical oncology.
2007;14(3):1161-9.
Epub 2007/01/02.
7.
Stangl R,
Altendorf-Hofmann A,
Charnley RM,
Scheele J.
Factors influencing the natural history of colorectal liver metastases.
Lancet.
1994;343(8910):1405-10.
Epub 1994/06/04.